Literature DB >> 9669502

GR231118 (1229U91) and other analogues of the C-terminus of neuropeptide Y are potent neuropeptide Y Y1 receptor antagonists and neuropeptide Y Y4 receptor agonists.

E M Parker1, C K Babij, A Balasubramaniam, R E Burrier, M Guzzi, F Hamud, G Mukhopadhyay, M S Rudinski, Z Tao, M Tice, L Xia, D E Mullins, B G Salisbury.   

Abstract

GR231118, BW1911U90, Bis(31/31')[[Cys31, Trp32, Nva34] neuropeptide Y(31-36)] (T-190) and [Trp-Arg-Nva-Arg-Tyr]2-NH2 (T-241) are peptide analogs of the C-terminus of neuropeptide Y that have recently been shown to be antagonists of the neuropeptide Y Y1 receptor. In this study, the activity of these peptides at each of the cloned neuropeptide Y receptor subtypes is determined in radioligand binding assays and in functional assays (inhibition of forskolin-stimulated cAMP formation). GR231118 is a potent antagonist at the human and rat neuropeptide Y Y1 receptors (pA2 = 10.5 and 10.0, respectively; pKi = 10.2 and 10.4, respectively), a potent agonist at the human neuropeptide Y Y4 receptor (pEC50 = 8.6; pKi = 9.6) and a weak agonist at the human and rat neuropeptide Y Y2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide Y Y6 receptor (pKi = 8.8). Therefore, GR231118 is a relatively selective neuropeptide Y Y1 receptor antagonist, but has appreciable activity at the neuropeptide Y Y4 and Y6 receptors as well. BW1911U90, T-190 and T-241 are moderately potent neuropeptide Y Y1 receptor antagonists (pA2 = 7.1, 5.8 and 6.5, respectively; pKi = 8.3, 6.5 and 6.8, respectively) and neuropeptide Y Y4 receptor agonists (pEC50 = 6.8, 6.3 and 6.6, respectively; pKi; 8.3, 7.7 and 8.3, respectively). These data suggest that the C-terminus of neuropeptide Y and related peptides is sufficient for activation of the neuropeptide Y Y4 receptor, but is not sufficient for activation of the neuropeptide Y Y1 receptor. Because BW1911U90, T-190 and T-241 are significantly less potent at the cloned human neuropeptide Y Y1 receptor than at the neuropeptide Y receptor in human erythroleukemia cells, these cells may express a novel neuropeptide Y receptor with high affinity for these peptides.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9669502     DOI: 10.1016/s0014-2999(98)00171-x

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  16 in total

1.  [(125)I]-GR231118: a high affinity radioligand to investigate neuropeptide Y Y(1) and Y(4) receptors.

Authors:  Y Dumont; R Quirion
Journal:  Br J Pharmacol       Date:  2000-01       Impact factor: 8.739

2.  BIIE0246, a potent and highly selective non-peptide neuropeptide Y Y(2) receptor antagonist.

Authors:  Y Dumont; A Cadieux; H Doods; L H Pheng; R Abounader; E Hamel; D Jacques; D Regoli; R Quirion
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

3.  Molecular identification of the long isoform of the human neuropeptide Y Y5 receptor and pharmacological comparison with the short Y5 receptor isoform.

Authors:  Marianne Rodriguez; Valérie Audinot; Sandra Dromaint; Christelle Macia; Véronique Lamamy; Philippe Beauverger; Hervé Rique; Jérôme Imbert; Jean Paul Nicolas; Jean A Boutin; Jean Pierre Galizzi
Journal:  Biochem J       Date:  2003-02-01       Impact factor: 3.857

4.  Agonist- and antagonist-induced sequestration/internalization of neuropeptide Y Y1 receptors in HEK293 cells.

Authors:  Leng Hong Pheng; Yvan Dumont; Alain Fournier; Jean-Guy Chabot; Alain Beaudet; Rémi Quirion
Journal:  Br J Pharmacol       Date:  2003-06       Impact factor: 8.739

5.  Enhancing functional production of G protein-coupled receptors in Pichia pastoris to levels required for structural studies via a single expression screen.

Authors:  Nicolas André; Nadia Cherouati; Cécile Prual; Tania Steffan; Gabrielle Zeder-Lutz; Thierry Magnin; Franc Pattus; Hartmut Michel; Renaud Wagner; Christoph Reinhart
Journal:  Protein Sci       Date:  2006-04-05       Impact factor: 6.725

6.  Agonist and antagonist activities on human NPFF(2) receptors of the NPY ligands GR231118 and BIBP3226.

Authors:  C Mollereau; C Gouardères; Y Dumont; M Kotani; M Detheux; H Doods; M Parmentier; R Quirion; J M Zajac
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

7.  Constitutive neuropeptide Y Y(4) receptor expression in human colonic adenocarcinoma cell lines.

Authors:  H M Cox; I R Tough; D W Zandvliet; N D Holliday
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

Review 8.  Physiological and Therapeutic Roles of Neuropeptide Y on Biological Functions.

Authors:  Pravin Shende; Drashti Desai
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

9.  Interaction of NPY compounds with the rat glucocorticoid-induced receptor (GIR) reveals similarity to the NPY-Y2 receptor.

Authors:  Renu Sah; Steven L Parker; Sulaiman Sheriff; Katherine Eaton; Ambikaipakan Balasubramaniam; Floyd R Sallee
Journal:  Peptides       Date:  2007-01-22       Impact factor: 3.750

10.  Development and characterization of a highly selective neuropeptide Y Y5 receptor agonist radioligand: [125I][hPP1-17, Ala31, Aib32]NPY.

Authors:  Yvan Dumont; Mira Thakur; Annette Beck-Sickinger; Alain Fournier; Rémi Quirion
Journal:  Br J Pharmacol       Date:  2003-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.